- Positive results from the STAM mouse model in vivo study attributing Thykamine™ with anti-MASH and anti-fibrosis effects in liver
- Compelling results compared to Resmetirom, the first FDA approved drug for management of MASH
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced a potential expanded therapeutic application for Thykamine™, with compelling preclinical data results demonstrating proof of concept efficacy in a well-established animal model of MASH metabolic dysfunction-associated steatohepatitis (MASH).
The study investigated the effects of Thykamine™ on liver disease progression in the widely used STAM mouse model of MASH/fibrosis at SMC Laboratories in Japan. In this model, diabetic mice were fed a high fat diet and rapidly to develop fatty liver disease caused by inflammation and a buildup of fat in the organ. Resmetirom, the first drug approved by US-FDA for the management of MASH, was used as positive control at an oral dose of 3.0 mg/kg once a day for 3 weeks.
Thykamine™ administered orally, at doses of 0.5 mg/kg, 5.0 mg/kg and 50.0 mg/kg, once a day for 3 weeks provided a hepatoprotective effect preventing liver disease progression compared to the control group (vehicle). Specifically, Thykamine™ treatment resulted in a significant lowering of the liver NAFLD activity score (NAS), a composite measure of fatty liver disease composed of steatosis, inflammation and hepatocyte ballooning. The α-SMA, a marker used to evaluate liver fibrosis, was also significantly decreased. Thykamine™ treatment decreased liver type collagen type I expression, collagen type III score, F4/F80 expression, Ly-6G expression and MARCO (macrophage receptor with collagen structure) expression. The effects on these markers were comparable to the effects of Resmeritom. Overall, progression of liver fibrosis was reduced by Thykamine™ treatment. Gene expression analysis data should be released shortly. The complete MASH preclinical results are planned to be submitted for publication in 2025.
Devonian Reports Positive Results in MASH Liver Study
- Positive results from the STAM mouse model in vivo study attributing Thykamine™ with anti-MASH and anti-fibrosis effects in liver
- Compelling results compared to Resmetirom, the first FDA approved drug for management of MASH
February 13, 2025 11:34 AM Eastern Standard Time
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced a potential expanded therapeutic application for Thykamine™, with compelling preclinical data results demonstrating proof of concept efficacy in a well-established animal model of MASH metabolic dysfunction-associated steatohepatitis (MASH).
The study investigated the effects of Thykamine™ on liver disease progression in the widely used STAM mouse model of MASH/fibrosis at SMC Laboratories in Japan. In this model, diabetic mice were fed a high fat diet and rapidly to develop fatty liver disease caused by inflammation and a buildup of fat in the organ. Resmetirom, the first drug approved by US-FDA for the management of MASH, was used as positive control at an oral dose of 3.0 mg/kg once a day for 3 weeks.
Thykamine™ administered orally, at doses of 0.5 mg/kg, 5.0 mg/kg and 50.0 mg/kg, once a day for 3 weeks provided a hepatoprotective effect preventing liver disease progression compared to the control group (vehicle). Specifically, Thykamine™ treatment resulted in a significant lowering of the liver NAFLD activity score (NAS), a composite measure of fatty liver disease composed of steatosis, inflammation and hepatocyte ballooning. The α-SMA, a marker used to evaluate liver fibrosis, was also significantly decreased. Thykamine™ treatment decreased liver type collagen type I expression, collagen type III score, F4/F80 expression, Ly-6G expression and MARCO (macrophage receptor with collagen structure) expression. The effects on these markers were comparable to the effects of Resmeritom. Overall, progression of liver fibrosis was reduced by Thykamine™ treatment. Gene expression analysis data should be released shortly. The complete MASH preclinical results are planned to be submitted for publication in 2025.
| Group | NAS(Mean ± SD | |
| Normal | 0.0 ± 0.0 | |
| Vehicule | 4.9 ± 0.6 | |
| Thykamine 0.5 mg/kg | 3.1 ± 1.0 | p < 0.05 |
| Thykamine 5.0 mg/kg | 2.9 ± 1.1 | p < 0.05 |
| Thykamine 50.0 mg/kg | 2.8 ± 0.9 | p < 0.05 |
| Resmetirom 3.0 mg/kg | 2.6 ± 0.7 | p < 0.05 |
“We are delighted with the outcome of this preclinical study and look forward to sharing more detail in a planned upcoming scientific publication. The data demonstrate an exciting proof of concept data of Thykamine™ anti-inflammatory and anti-fibrotic effects in MASH. Historical preclinical and clinical studies of Thykamine™ have demonstrated its anti-inflammatory properties. The anti-fibrotic MASH data adds an important key complementary feature of Thykamine™ mechanism of action. In inflammatory diseases, fibrosis typically develops in response to repeated injuries or chronic inflammation. The MASH study demonstrates that Thykamine™ has anti-inflammatory and anti-fibrotic effects with the potential to target underlying disease pathology and therefore stop the progression of the disease”, said Dr. Andre P. Boulet, PhD, Chief Scientific Officer of the Company.
“This is one more study in the arsenal of Thykamine™, demonstrating its multi targeting mode of action affecting the cytokines affecting inflammation, opening up a broad array of possible applications for our lead product in underserved auto immune inflammatory diseases, which now adds hepatic conditions to our other targets such as dermatology and IBD”, said Luc Gregoire, president and CEO of the Company.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
